The LPAM-1 Receptor: A Potential Drug Target for Cancer and Inflammation

Target Name: Integrin alpha4beta7 (LPAM-1) receptor

NCBI ID: P5761

Other Name(s): LPAM-1 | alpha4beta7 | alpha4beta7 receptor

The LPAM-1 Receptor: A Potential Drug Target for Cancer and Inflammation

The Integrin alpha4beta7 (LPAM-1) receptor is a protein that is expressed in many different tissues throughout the body. It is a member of the integrin family, which is a group of transmembrane proteins that play a critical role in cell-cell and cell-extracellular matrix interactions. The LPAM-1 receptor is involved in many different processes in the body, including cell adhesion, migration, and angiogenesis.

Recent studies have suggested that the LPAM-1 receptor may be a drug target or biomarker for a variety of diseases. For example, some studies have suggested that inhibiting the activity of the LPAM-1 receptor may be a promising approach for treating cancer, as it has been shown to be involved in the development and progression of many types of cancer. Additionally, the LPAM-1 receptor has also been suggested as a potential biomarker for monitoring the effectiveness of anti-inflammatory treatments.

The LPAM-1 receptor is a transmembrane protein that is composed of two subunits: alpha-4 and beta-7. The alpha-4 subunit is the most abundant subunit, and it is involved in the formation of the extracellular matrix (ECM). The beta-7 subunit is also important for the function of the LPAM-1 receptor, as it is involved in the interaction with ECM components.

The LPAM-1 receptor is involved in many different processes in the body. For example, it is involved in cell adhesion and migration, which are critical processes for the development and progression of many types of cancer. The LPAM-1 receptor has been shown to be involved in the development of breast cancer, as well as in the development and progression of other types of cancer.

In addition to its role in cancer development, the LPAM-1 receptor is also involved in the regulation of inflammation. In fact, the beta-7 subunit of the LPAM-1 receptor has been shown to be involved in the production of pro-inflammatory cytokines. This suggests that the LPAM-1 receptor may be a potential target for anti-inflammatory treatments.

The LPAM-1 receptor has also been suggested as a potential drug target for treating a variety of diseases. For example, some studies have suggested that inhibiting the activity of the LPAM-1 receptor may be a promising approach for treating cancer, as it has been shown to be involved in the development and progression of many types of cancer. Additionally, the LPAM-1 receptor has also been suggested as a potential biomarker for monitoring the effectiveness of anti-inflammatory treatments.

In conclusion, the Integrin alpha4beta7 (LPAM-1) receptor is a protein that is involved in many different processes in the body. Recent studies have suggested that it may be a drug target or biomarker for a variety of diseases, including cancer and inflammation. Further research is needed to fully understand the role of the LPAM-1 receptor in the body, and to develop effective treatments for diseases that are caused by its dysfunction.

Protein Name: Integrin Alpha4beta7 (LPAM-1) Receptor

More Common Targets